Skip to main content

Table 3 Severe (grade 3–4) acute toxicity during concurrent chemotherapy and late toxicity during follow up

From: Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Adverse event Entire cohort (n, %) CC-CCD group (n, %) P valuea
< 160 mg/m2 ≥ 160 mg/m2
Acute toxicity (n = 132)   n = 52 n = 80  
 Mucositis 57 (43.2) 21 (40.4) 36 (45.0) 0.719
 Nausea 23 (17.4) 10 (19.2) 13 (16.3) 0.648
 Leucopenia 35 (26.5) 14 (26.9) 21 (26.3) 0.996
 Neutropenia 18 (13.6) 9 (17.3) 9 (11.3) 0.437
 Anemia 5 (3.8) 1 (1.9) 4 (5.0) 0.648
 Thrombocytopenia 2 (1.5) 1 (1.9) 1 (1.3) 0.997
Late toxicity (n = 115)   n = 43 n = 72  
 Xerostomia 11 (9.6) 5 (11.6) 6 (8.3) 0.723
 Ototoxicity 9 (7.8) 4 (9.3) 5 (6.9) 0.726
 Neck fibrosis 6 (5.2) 2 (4.7) 4 (5.6) 0.992
 Hypothyroidism 3 (2.6) 2 (4.7) 1 (1.4) 0.555
  1. CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy
  2. aP values were calculated using the chi-square test or Fisher exact test if indicated